Drug Profile
Research programme: endocrine disorders therapy - Dong-A Pharmaceutical
Alternative Names: DA-3003Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A ST
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dwarfism
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dwarfism in South Korea (Parenteral, Injection)